Royal Sisters Withdraw from London's Met Gala Event
Princesses Beatrice and Eugenie have unexpectedly pulled out of the highly anticipated high society ball, leaving organisers scrambling just days before the event dubbed 'London's Met Gala'.
Category : Search result: Royal Pharmaceutical Society
Prince Andrew's £37M fortune revealed despite royal exile
Exclusive investigation uncovers how the Duke of York maintains his multi-million pound fortune through royal inheritance and property portfolio despite stepping back from public duties.
Ben Smith appointed Newcastle Building Society CEO
Newcastle Building Society announces Ben Smith as incoming Chief Executive, bringing extensive financial services experience to lead the mutual's next chapter of growth and member-focused strategy.
Trump pressured AstraZeneca on US drug prices
Exclusive investigation reveals how Donald Trump pressured AstraZeneca to slash US drug prices while keeping UK costs high, exposing stark transatlantic healthcare divide.
RHS warning: Poisonous mushrooms in UK gardens
The Royal Horticultural Society alerts gardeners about dangerous shaggy parasol mushrooms appearing unexpectedly in gardens across Britain, following multiple poisoning incidents.
Indian pharma execs arrested in cough syrup death scandal
Indian authorities have detained three pharmaceutical executives following an investigation into contaminated cough syrup allegedly responsible for numerous child deaths in Cameroon.
Princess Beatrice attends lavish Long Island wedding
Princess Beatrice makes rare US appearance at lavish Long Island wedding, showcasing impeccable style and royal grace while supporting close friend in intimate ceremony.
NHS drug bill may rise £1bn due to Trump tariffs
Exclusive investigation reveals how potential Trump tariffs could devastate NHS medicine budgets while pharmaceutical giants reconsider UK investments over pricing disputes.
Big Pharma's Legal War Threatens NHS Drug Access
Pharmaceutical giants are launching an unprecedented legal assault against the UK government, threatening NHS access to vital medicines and putting patient care at risk in a battle over drug pricing.
Weight-Loss Jabs: The Profit-Driven Health Crisis
Exclusive investigation reveals how drug companies are profiting from body shame through Ozempic and Wegovy injections, while eating disorder experts warn of potentially devastating health consequences.
GSK's Growth Gamble: Walmsley's Steady Hand Faces Test
Five years into her tenure, CEO Emma Walmsley has stabilised GSK's ship, but looming patent cliffs and vaccine market pressures cast shadows over ambitious growth targets.
Six-month HIV prevention jab for 120 countries by 2027
A groundbreaking HIV prevention injection offering six months of protection with lenacapavir will be available in 120 lower-income countries by 2027 through a landmark access agreement.
UK Worst in Europe for Drug Prices, Says Eli Lilly
Eli Lilly accuses the UK of having Europe's most challenging drug pricing system, threatening patient access to new medicines like Mounjaro amid ongoing NHS negotiations.
Gold Prices Surge as Pharma Stocks Face Pressure
Financial markets experienced significant volatility as gold hit record highs while pharmaceutical giant Eli Lilly faced pressure over drug pricing concerns. Get the latest analysis on today's market movements.
Trump's Tylenol Gaffe Sends Wall Street into Frenzy
Former President Donald Trump's confusion between Tylenol and hydroxychloroquine during the presidential debate triggers a sharp sell-off in pharmaceutical stocks, with Kenvue shares taking a significant hit.
Tylenol makers hit back at Trump's vaccine comparison
Pharmaceutical giant Kenvue has issued a stern rebuke to Donald Trump after he suggested the COVID-19 vaccine was comparable to the Tylenol murders, calling the analogy 'irresponsible'.
Kate Middleton Honoured with New RHS Rose
The Princess of Wales has collaborated with the RHS to introduce a beautiful new rose named in her honour. Discover the story behind this scented, blush-pink flower and how you can see it at the Chelsea Flower Show.
RHS Cuts French Lavender From Pollinator List in Major Shift
The Royal Horticultural Society is reclassifying thousands of garden plants, moving away from non-native species like French lavender to prioritise UK wildlife-friendly varieties in a major sustainability shift.
Chinese Executive Jailed in US Fentanyl Case
A senior Chinese pharmaceutical executive has been sentenced to 15 years in a US prison for conspiring to manufacture and distribute fentanyl, marking a significant victory in the transatlantic fight against the opioid crisis.
NHS Drug Pricing: The Art of the Deal Saving Millions
Exclusive insight into how NHS England's shrewd negotiation tactics secure massive discounts on vital medicines, from cancer treatments to rare disease drugs, ensuring sustainable healthcare funding.
New Weight Loss Pill Cuts Body Weight By 20%
Breakthrough obesity drug Orforglipron shows unprecedented results in clinical trials, reducing body weight by a fifth and offering new hope for millions struggling with weight management in the UK.
NHS Must Reverse Medicines Investment Decline - Minister
Former chief scientific adviser Sir Patrick Vallance warns that dwindling investment in medical research and innovation threatens the future of the NHS and patient care. Discover the urgent call for action.
AstraZeneca shifts cancer drug production from UK to Ireland
Pharmaceutical giant Merck to manufacture flagship cancer drug Lynparza at new €1 billion Irish facility, dealing significant blow to UK's life sciences sector and raising fresh post-Brexit trade concerns.
Trump Threatens NHS Drug Pricing: UK Faces US Medicine Costs
Exclusive analysis reveals how a potential Trump presidency could jeopardise Britain's NHS medicine pricing, forcing UK patients to pay US-style pharmaceutical costs.
Big Pharma's Billion-Pound Bet on Post-Trump UK
Major pharmaceutical giants AstraZeneca, MSD (Merck), and Eli Lilly announce massive new investments in UK research and manufacturing, signalling a major vote of confidence in the British life sciences sector following the US election result.
AstraZeneca Pauses £500m Cambridge HQ Investment
Pharmaceutical giant AstraZeneca has paused plans for its new £500 million global headquarters in Cambridge, citing an 'unfavourable' UK economic climate and sending shockwaves through the business community.
Common Meds Linked to Youth Suicide Surge, Study Finds
Groundbreaking research uncovers a disturbing correlation between widely prescribed drugs, including beta-blockers and anti-anxiety medications, and a sharp increase in suicide risks and depression in children and young adults. Experts are calling for urg
AstraZeneca Pauses £200m Cambridge Research Investment
Pharmaceutical giant AstraZeneca pauses its major £200m Cambridge research centre expansion, citing global strategic review and UK economic uncertainty in post-Brexit landscape.
Sanofi CEO: UK is 'terrible place' for medicines
Sanofi executive warns of UK's worsening medicines access crisis, citing post-Brexit regulations, NICE hurdles, and a pricing system that deters investment and innovation.
MSD to create 125+ new R&D jobs in London expansion
Pharmaceutical giant MSD, known as Merck in the US, is significantly expanding its UK presence with a new state-of-the-art research hub in London, generating over 125 new high-skilled jobs and reinforcing the city's status as a global life sciences leader
Page 2 of 4